<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:voc="urn:hl7-org:v3/voc" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="634dd03b-9fa7-479e-1045-d48dea0b7892"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use DOXYCYCLINE HYCLATE TABLETS safely and effectively. See full prescribing information for DOXYCYCLINE HYCLATE TABLETS. <br/>
         <br/>DOXYCYCLINE HYCLATE tablets, for oral use <br/>Initial U.S. Approval: 1967</content>
      <br/>
      <br/>  <content styleCode="bold"/>
   </title>
   <effectiveTime value="20250411"/>
   <setId root="2aa7ec9a-94b7-2f89-0d52-af9ec610b8fa"/>
   <versionNumber value="6"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="845263701" root="1.3.6.1.4.1.519.1"/>
            <name>Apotex Corp.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="209429182" root="1.3.6.1.4.1.519.1"/>
                  <name>Apotex Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="209429182" root="1.3.6.1.4.1.519.1"/>
                        <name>Apotex Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4382" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4382" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4384" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4384" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="16f6897b-4c14-4c5d-e6b4-a25986cabc21"/>
               <code code="48780-1" displayName="SPL PRODUCT DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250411"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-4382" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Doxycycline Hyclate</name>
                        <formCode code="C42897" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Doxycycline Hyclate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="75"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="19XTS3T51U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DOXYCYCLINE HYCLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="334895S862" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Doxycycline Anhydrous</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM </name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE </name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE </name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="35SW5USQ3G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C YELLOW NO. 10</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4382-6"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20190801"/>
                                    <high value="20251231"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4382-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20190801"/>
                                    <high value="20190801"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="500"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4382-5"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20190801"/>
                                    <high value="20190801"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20190801"/>
                              <high value="20251231"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA209243" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" displayName="BLUE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>Light teal</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;D75</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-4384" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Doxycycline Hyclate</name>
                        <formCode code="C42897" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Doxycycline Hyclate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="150"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="19XTS3T51U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DOXYCYCLINE HYCLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="334895S862" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Doxycycline Anhydrous</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM </name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE </name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE </name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4384-6"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20190801"/>
                                    <high value="20251231"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4384-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20190801"/>
                                    <high value="20190801"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="500"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4384-5"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20190801"/>
                                    <high value="20190801"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20190801"/>
                              <high value="20251231"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA209243" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" displayName="GREEN" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>Mossy green</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="3" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">A;P;O;1;5;0</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <section>
                     <id root="ab695347-f5ce-28d8-73ed-fad71bf9876f"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <effectiveTime value="20160212"/>
                     <component>
                        <observationMedia ID="MM526342451398">
                           <text>structure</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="structure.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM527326191201">
                           <text>150-mg-treatment</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="150-mg-treatment.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM694501683217">
                           <text>100-mg-treatment</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="100-mg-treatment.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM300771129067">
                           <text>50-mg-treatment</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="50-mg-treatment.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM245582140766">
                           <text>btl-lbl-75mg-60s</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="btl-lbl-75mg-60s.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM947205434919">
                           <text>btl-lbl-150mg-60s</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="btl-lbl-150mg-60s.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_ddd59e50-15bf-825b-e6f8-bc258f8f13aa">
               <id root="fa4917cc-ad9c-3a47-b6dd-d1a1ada66377"/>
               <code code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20200531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Doxycycline hyclate tablets are tetracycline class drugs indicated for: </paragraph>
                        <list>
                           <item>Rickettsial infections (<linkHtml href="#_804059b0-a7cc-5eae-1a13-3229d23409b1">1.1</linkHtml>)</item>
                           <item>Sexually transmitted infections (<linkHtml href="#_fc390786-3d73-3059-081b-709d6dfaac1b">1.2</linkHtml>)</item>
                           <item>Respiratory tract infections (<linkHtml href="#_28a3cb0a-025c-8d80-2cad-43dc855d4bb6">1.3</linkHtml>)</item>
                           <item>Specific bacterial infections (<linkHtml href="#_7171ea40-14e2-b9a9-15f0-8f73ee89a6b6">1.4</linkHtml>)</item>
                           <item>Ophthalmic infections (<linkHtml href="#_628cc237-c0ff-16b0-8b9e-492d1d6bb27c">1.5</linkHtml>)</item>
                           <item>Anthrax, including inhalational anthrax (post-exposure) (<linkHtml href="#_1cb665cd-e30b-9ec3-588d-029084f3ec72">1.6</linkHtml>)</item>
                           <item>Alternative treatment for selected infections when penicillin is contraindicated (<linkHtml href="#_4a9eb6e1-973f-14c2-db7f-4d26319519c4">1.7</linkHtml>)</item>
                           <item>Adjunctive therapy for acute intestinal amebiasis and severe acne (<linkHtml href="#_9699ab18-62cf-b118-4d5c-8b198bd88203">1.8</linkHtml>)</item>
                           <item>Prophylaxis of malaria (<linkHtml href="#_34773768-6eaa-c7d1-fbf2-202d61118f97">1.9</linkHtml>)</item>
                        </list>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (<linkHtml href="#_46197b38-ea05-8bea-9fe9-fb463a650979">1.10</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_804059b0-a7cc-5eae-1a13-3229d23409b1">
                     <id root="0a562e42-65ac-d706-a9d3-f11b723d4cb4"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.1 Rickettsial Infections</title>
                     <text>
                        <paragraph>Doxycycline hyclate tablets are indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox, and tick fevers caused by <content styleCode="italics">Rickettsiae</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_fc390786-3d73-3059-081b-709d6dfaac1b">
                     <id root="557910fd-edc3-45bd-7010-264982d1bdd0"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.2 Sexually Transmitted Infections</title>
                     <text>
                        <paragraph>Doxycycline hyclate tablets are indicated for treatment of the following sexually transmitted infections:</paragraph>
                        <list>
                           <item>Uncomplicated urethral, endocervical or rectal infections caused by <content styleCode="italics">Chlamydia trachomatis</content>.</item>
                           <item>Nongonococcal urethritis caused by <content styleCode="italics">Ureaplasma urealyticum</content>.</item>
                           <item>Lymphogranuloma venereum caused by <content styleCode="italics">Chlamydia trachomatis</content>. </item>
                           <item>Granuloma inguinale caused by <content styleCode="italics">Klebsiella granulomatis</content>.</item>
                           <item>Uncomplicated gonorrhea caused by <content styleCode="italics">Neisseria gonorrhoeae</content>. </item>
                           <item>Chancroid caused by <content styleCode="italics">Haemophilus ducreyi</content>. </item>
                        </list>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_28a3cb0a-025c-8d80-2cad-43dc855d4bb6">
                     <id root="26921239-306f-8136-2ec4-584f05284b42"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.3 Respiratory Tract Infections</title>
                     <text>
                        <paragraph>Doxycycline hyclate tablets are indicated for treatment of the following respiratory tract infections:</paragraph>
                        <list>
                           <item>Respiratory tract infections caused by <content styleCode="italics">Mycoplasma pneumoniae</content>.</item>
                           <item>Psittacosis (ornithosis) caused by <content styleCode="italics">Chlamydophila psittaci</content>.</item>
                           <item>Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.</item>
                           <item>Doxycycline is indicated for treatment of infections caused by the following microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug:</item>
                           <item>Respiratory tract infections caused by <content styleCode="italics">Haemophilus influenzae. </content>
                           </item>
                           <item>Respiratory tract infections caused by <content styleCode="italics">Klebsiella species</content>.</item>
                           <item>Upper respiratory infections caused by <content styleCode="italics">Streptococcus pneumoniae</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_7171ea40-14e2-b9a9-15f0-8f73ee89a6b6">
                     <id root="ab9b3d77-b7c3-4f3f-b084-e30eb02a1c47"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.4 Specific Bacterial Infections</title>
                     <text>
                        <paragraph>Doxycycline hyclate tablets are indicated for treatment of the following specific bacterial infections:</paragraph>
                        <list>
                           <item>Relapsing fever due to <content styleCode="italics">Borrelia recurrentis</content>.</item>
                           <item>Plague due to <content styleCode="italics">Yersinia pestis</content>.</item>
                           <item>Tularemia due to <content styleCode="italics">Francisella tularensis</content>. </item>
                           <item>Cholera caused by <content styleCode="italics">Vibrio cholerae</content>.</item>
                           <item>Campylobacter fetus infections caused by <content styleCode="italics">Campylobacter fetus</content>. </item>
                           <item>Brucellosis due to <content styleCode="italics">Brucella</content> species (in conjunction with streptomycin).</item>
                           <item>Bartonellosis due to <content styleCode="italics">Bartonella bacilliformis</content>. </item>
                        </list>
                        <paragraph>Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.</paragraph>
                        <paragraph>Doxycycline hyclate tablets are indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug:</paragraph>
                        <list>
                           <item>
                              <content styleCode="italics">Escherichia coli </content>
                           </item>
                           <item>
                              <content styleCode="italics">Enterobacter aerogenes</content>
                           </item>
                           <item>
                              <content styleCode="italics">Shigella</content> species </item>
                           <item>
                              <content styleCode="italics">Acinetobacter</content> species</item>
                           <item>Urinary tract infections caused by <content styleCode="italics">Klebsiella</content> species.</item>
                        </list>
                        <paragraph/>
                        <paragraph/>
                        <paragraph/>
                        <paragraph/>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_628cc237-c0ff-16b0-8b9e-492d1d6bb27c">
                     <id root="4fa33640-7dd8-e30e-8e05-9d172ec5fa3d"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.5 Ophthalmic Infections</title>
                     <text>
                        <paragraph>Doxycycline hyclate tablets are indicated for treatment of the following ophthalmic infections:</paragraph>
                        <list>
                           <item>Trachoma caused by <content styleCode="italics">Chlamydia trachomatis</content>, although the infectious agent is not always eliminated as judged by immunofluorescence.</item>
                           <item>Inclusion conjunctivitis caused by <content styleCode="italics">Chlamydia trachomatis</content>.</item>
                        </list>
                        <paragraph/>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_1cb665cd-e30b-9ec3-588d-029084f3ec72">
                     <id root="7eede759-3c9f-c03f-5fbf-eac1e093f1cd"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.6 Anthrax Including Inhalational Anthrax (Post-Exposure)</title>
                     <text>
                        <paragraph>Doxycycline hyclate tablets are indicated for the treatment of Anthrax due to <content styleCode="italics">Bacillus anthracis</content>, including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized <content styleCode="italics">Bacillus anthracis</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_4a9eb6e1-973f-14c2-db7f-4d26319519c4">
                     <id root="b3663d10-f9df-792f-f970-a25d33c3946d"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.7 Alternative Treatment for Selected Infections when Penicillin is Contraindicated</title>
                     <text>
                        <paragraph>Doxycycline hyclate tablets are indicated as an alternative treatment for the following selected infections when penicillin is contraindicated:</paragraph>
                        <list>
                           <item>Syphilis caused by <content styleCode="italics">Treponema pallidum</content>.</item>
                           <item>Yaws caused by <content styleCode="italics">Treponema pallidum</content> subspecies <content styleCode="italics">pertenue</content>. </item>
                           <item>Listeriosis due to <content styleCode="italics">Listeria monocytogenes</content>.</item>
                           <item>Vincent’s infection caused by <content styleCode="italics">Fusobacterium fusiforme</content>. </item>
                           <item>Actinomycosis caused by <content styleCode="italics">Actinomyces israelii</content>. </item>
                           <item>Infections caused by <content styleCode="italics">Clostridium species</content>.</item>
                        </list>
                        <paragraph/>
                        <paragraph/>
                        <paragraph/>
                        <paragraph/>
                        <paragraph/>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_9699ab18-62cf-b118-4d5c-8b198bd88203">
                     <id root="fefb6886-ef4f-a50c-8c27-dce8354cdf13"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.8 Adjunctive Therapy for Acute Intestinal Amebiasis and Severe Acne</title>
                     <text>
                        <paragraph>In acute intestinal amebiasis, doxycycline hyclate tablets may be a useful adjunct to amebicides. </paragraph>
                        <paragraph>In severe acne, doxycycline hyclate tablets may be useful adjunctive therapy.</paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_34773768-6eaa-c7d1-fbf2-202d61118f97">
                     <id root="0aec906b-f056-8029-eb51-c51a98e1baa4"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.9 Prophylaxis of Malaria</title>
                     <text>
                        <paragraph>Doxycycline hyclate tablets are indicated for the prophylaxis of malaria due to <content styleCode="italics">Plasmodium falciparum</content> in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#_ea1e7600-b325-d501-c67a-34121a6baaf2">2.4</linkHtml>) and Patient Counseling Information (<linkHtml href="#INFORMATION_FOR_PATIENTS">17</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_46197b38-ea05-8bea-9fe9-fb463a650979">
                     <id root="ff952c8f-2ce3-07b4-6abe-c63653b2dd83"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.10 Usage</title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate tablets and other antibacterial drugs, doxycycline hyclate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="DOSAGE_AND_ADMINISTRATION">
               <id root="a22a1335-e05d-5190-b65b-f4f15268bd20"/>
               <code code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20200531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <list>
                           <item>
                              <content styleCode="underline">Important Administration Instructions for Doxycycline Hyclate Tablets</content>
                              <list>
                                 <item>Doxycycline hyclate tablets (150 mg) can be broken into two-thirds or one-third to provide a 50 mg and 100 mg strength, respectively. (<linkHtml href="#_c0cc4249-f019-6d60-f53c-a0a160f6a9f9">2.1</linkHtml>)</item>
                              </list>
                           </item>
                        </list>
                        <list>
                           <item>
                              <content styleCode="underline">Dosage in Adults for Doxycycline Hyclate Tablets</content>
                              <list>
                                 <item>The usual dosage is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg daily. (<linkHtml href="#_c0cc4249-f019-6d60-f53c-a0a160f6a9f9">2.1</linkHtml>)</item>
                                 <item>In the management of more severe infections (particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended. (<linkHtml href="#_c0cc4249-f019-6d60-f53c-a0a160f6a9f9">2.1</linkHtml>)</item>
                              </list>
                           </item>
                        </list>
                        <list>
                           <item>
                              <content styleCode="underline">Dosage in Pediatric Patients for Doxycycline Hyclate Tablets:</content>
                              <list>
                                 <item>For all pediatric patients weighing less than 45 kg with severe or life-threatening infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended dose is 2.2 mg per kg of body weight administered every 12 hours. Pediatric patients weighing 45 kg or more should receive the adult dose. (<linkHtml href="#_0b9d9d30-39a4-afb7-9662-04eaecf2f0cb">2.3</linkHtml>)</item>
                                 <item>For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dose is 4.4 mg per kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg per kg of body weight given as a single daily dose or divided into two doses. For pediatric patients weighing over 45 kg, the usual adult dose should be used. (<linkHtml href="#_0b9d9d30-39a4-afb7-9662-04eaecf2f0cb">2.3</linkHtml>)</item>
                              </list>
                           </item>
                        </list>
                        <list>
                           <item>See Full Prescribing Information for additional indication specific dosage information and important administration instructions for doxycycline hyclate tablets. (<linkHtml href="#_c0cc4249-f019-6d60-f53c-a0a160f6a9f9">2.1</linkHtml>,<linkHtml href="#_ea1e7600-b325-d501-c67a-34121a6baaf2"> 2.4</linkHtml>, <linkHtml href="#_0b9d9d30-39a4-afb7-9662-04eaecf2f0cb">2.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_c0cc4249-f019-6d60-f53c-a0a160f6a9f9">
                     <id root="4abb91a1-89b5-7e39-2e5b-ffa1f56fcbfc"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.1 Important Administration Instructions</title>
                     <text>
                        <paragraph/>
                        <list>
                           <item>The usual dosage and frequency of administration of doxycycline hyclate tablets differs from that of the other tetracyclines. Exceeding the recommended dosage may result in an increased incidence of adverse reactions.</item>
                           <item>Administer doxycycline hyclate tablets with adequate amounts of fluid to wash down the drugs and reduce the risk of esophageal irritation and ulceration <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ADVERSE_REACTIONS">6</linkHtml>)].</content>
                           </item>
                           <item>If gastric irritation occurs, doxycycline hyclate tablets may be given with food or milk <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>)]</content>
                           </item>
                           <item>Doxycycline hyclate tablets (150 mg) can be broken into two-thirds or one-third to provide a 100 mg and 50 mg strength, respectively <content styleCode="italics">[see FDA-approved patient labeling].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_64f8d0db-71ff-d488-c4da-bbe876af5215">
                     <id root="7d461d32-c31f-0b40-2a33-c61033eb3272"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.2 Dosage in Adult Patients</title>
                     <text>
                        <paragraph/>
                        <list>
                           <item>The usual dosage of doxycycline hyclate tablets is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg daily. The maintenance dose may be administered as a single dose or as 50 mg every 12 hours. </item>
                           <item>In the management of more severe infections (particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended.</item>
                           <item>For certain selected specific indications, the recommended duration or dosage and duration of doxycycline hyclate tablets in adult patients are as follows:</item>
                        </list>
                        <paragraph>1. Streptococcal infections, therapy should be continued for 10 days.</paragraph>
                        <paragraph>2. Uncomplicated urethral, endocervical, or rectal infection caused by <content styleCode="italics">Chlamydia trachomatis:</content> 100 mg by mouth twice-a-day for 7 days.</paragraph>
                        <paragraph>3. Uncomplicated gonococcal infections in adults (except anorectal infections in men): 100 mg, by mouth, twice-a-day for 7 days. As an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose.</paragraph>
                        <paragraph>4. Nongonococcal urethritis (NGU) caused by <content styleCode="italics">C. trachomatis</content> and <content styleCode="italics">U. urealyticum:</content> 100 mg by mouth twice-a-day for 7 days.</paragraph>
                        <paragraph>5. Syphilis – early: Patients who are allergic to penicillin should be treated with doxycycline 100 mg by mouth twice-a-day for 2 weeks.</paragraph>
                        <paragraph>6. Syphilis of more than one year’s duration: Patients who are allergic to penicillin should be treated with doxycycline 100 mg by mouth twice-a-day for 4 weeks.</paragraph>
                        <paragraph>7. Acute epididymo-orchitis caused by <content styleCode="italics">N. gonorrhoeae:</content> 100 mg by mouth, twice-a-day for at least 10 days. </paragraph>
                        <paragraph>8. Acute epididymo-orchitis caused by <content styleCode="italics">C. trachomatis:</content> 100 mg, by mouth, twice-a-day for at least 10 days.</paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_fd09f9a1-d604-1ed1-4570-220593ce7eb6">
                     <id root="168bed3d-7a1f-1bac-a3ca-6c2802839207"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.3	Dosage in Pediatric Patients</title>
                     <text>
                        <paragraph/>
                        <list>
                           <item>For all pediatric patients weighing less than 45 kg with severe or life threatening infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended dosage of doxycycline hyclate tablets is 2.2 mg per kg of body weight administered every 12 hours. Pediatric patients weighing 45 kg or more should receive the adult dose <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_d193ecd5-24b0-f016-fb8f-c8f6e58c0425">5.1</linkHtml>)].</content>
                           </item>
                           <item>For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule of doxycycline hyclate tablets is 4.4 mg per kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg per kg of body weight (given as a single daily dose or divided into twice daily doses). For pediatric patients weighing over 45 kg, the usual adult dose should be used.</item>
                        </list>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_ea1e7600-b325-d501-c67a-34121a6baaf2">
                     <id root="2a448ba7-d9eb-dee7-2e49-e9ee669f1c65"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.4 Dosage for Prophylaxis of Malaria</title>
                     <text>
                        <paragraph>For adults, the recommended dose of doxycycline hyclate tablets is 100 mg daily. </paragraph>
                        <paragraph>For pediatric patients 8 years of age and older, the recommended dosage of doxycycline hyclate tablets is 2 mg per kg of body weight administered once daily. Pediatric patients weighing 45 kg or more should receive the adult dose. Prophylaxis should begin 1 or 2 days before travel to the malarious area. Prophylaxis should be continued daily during travel in the malarious area and for 4 weeks after the traveler leaves the malarious area.</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_0b9d9d30-39a4-afb7-9662-04eaecf2f0cb">
                     <id root="cca956ca-b69b-2f8b-ed91-774dc0e56586"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.5 Dosage for Inhalational Anthrax (Post-Exposure)</title>
                     <text>
                        <paragraph>For adults, the recommended dosage is 100 mg, of doxycycline hyclate tablets, by mouth, twice-a-day for 60 days.</paragraph>
                        <paragraph>For pediatric patients weighing less than 45 kg, the recommended dosage of doxycycline hyclate tablets is 2.2 mg per kg of body weight, by mouth, twice-a-day for 60 days. Pediatric patients weighing 45 kg or more should receive the adult dose.</paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="DOSAGE_FORMS_AND_STRENGTHS">
               <id root="3d7c6a0e-1b61-75bb-cd94-acdfa111414f"/>
               <code code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Doxycycline hyclate tablets, USP 75 mg are light teal, round, biconvex film-coated tablets. Engraved "APO" on one side, "D75" on the other side. </paragraph>
                  <paragraph>Doxycycline hyclate tablets, USP 150 mg are mossy green, capsule shaped, biconvex film-coated tablets. Engraved "A" bisect "P" bisect "O" on one side, "1" bisect "5" bisect "0" on the other side. Each side of the functionally scored tablet has two parallel score lines for splitting into 3 equal portions.</paragraph>
               </text>
               <effectiveTime value="20200531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets, 75 mg and 150 mg (functionally scored) (<linkHtml href="#DOSAGE_FORMS_AND_STRENGTHS">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="CONTRAINDICATIONS">
               <id root="0f95f160-aeaf-5387-5c11-8fb5f3b449a3"/>
               <code code="34070-3" displayName="CONTRAINDICATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Doxycycline hyclate tablets are contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.</paragraph>
               </text>
               <effectiveTime value="20200531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Doxycycline is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. (<linkHtml href="#CONTRAINDICATIONS">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="WARNINGS_AND_PRECAUTIONS">
               <id root="dd4ebd63-a2c2-0500-e257-71ef3dbeb1f5"/>
               <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20180814"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <list>
                           <item>The use of doxycycline hyclate tablets during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia. Advise the patient of the potential risk to the fetus during pregnancy (<linkHtml href="#_64f8d0db-71ff-d488-c4da-bbe876af5215">2.2</linkHtml>, <linkHtml href="#_d193ecd5-24b0-f016-fb8f-c8f6e58c0425">5.1, </linkHtml>
                              <linkHtml href="#PREGNANCY">8.1</linkHtml>
                              <linkHtml href="#_d193ecd5-24b0-f016-fb8f-c8f6e58c0425">, </linkHtml>
                              <linkHtml href="#PEDIATRIC_USE">8.4</linkHtml>)</item>
                           <item>The use of Doxycycline Hyclate tablets during the second and third-trimester of pregnancy, infancy and childhood up to the age of 8 years of age may cause reversible inhibition of bone growth. Advise the patient of the potential risk to the fetus during pregnancy. (<linkHtml href="#_5015b3fe-02ce-7014-c993-3eb0a4a250b6">5.2,</linkHtml>
                              <linkHtml href="#PREGNANCY">8.1</linkHtml>, <linkHtml href="#NURSING_MOTHERS">8.4</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Clostridioides difficile</content>-associated diarrhea (CDAD) has been reported. Evaluate patients if diarrhea occurs. (<linkHtml href="#_e69316e7-1cdc-84b2-ec47-5ac38131e236">5.3</linkHtml>)</item>
                           <item>Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Limit sun exposure. (<linkHtml href="#_689b21e3-de32-f161-0d0b-e9c642681e20">5.3</linkHtml>)</item>
                           <item>Overgrowth of non-susceptible organisms, including fungi, may occur. If such infections occur, discontinue use and institute appropriate therapy. (<linkHtml href="#_b8327f04-d420-2c8d-9087-40a5c4178958">5.10</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_d193ecd5-24b0-f016-fb8f-c8f6e58c0425">
                     <id root="8840c737-881a-1cd0-cf30-b99fea9f93ef"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.1 Tooth Development</title>
                     <text>
                        <paragraph>The use of doxycycline hyclate tablets during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs of the tetracycline-class, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported with drugs of the tetracycline-class.Advise the patient of the potential risk to the fetus if doxycycline hyclate tablets if used during pregnancy [see Use in <content styleCode="italics">Specific Populations (</content>
                           <linkHtml href="#PREGNANCY">8.1</linkHtml>,<linkHtml href="#PEDIATRIC_USE">8.4</linkHtml>)]. </paragraph>
                        <paragraph>Use doxycycline hyclate tablets in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="_5015b3fe-02ce-7014-c993-3eb0a4a250b6">
                     <id root="551c4279-0f1e-8759-4be8-c348731cfe4c"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.2 Inhibition of Bone Growth</title>
                     <text>
                        <paragraph>The use of doxycycline hyclate tablets during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth. All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in premature infants given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued. Advise the patient of the potential risk to the fetus if doxycycline hyclate tablets is used during pregnancy [see Use in Specific Populations (<linkHtml href="#PREGNANCY">8.1</linkHtml>,<linkHtml href="#PEDIATRIC_USE"> 8.4</linkHtml>)].</paragraph>
                     </text>
                     <effectiveTime value="20200803"/>
                  </section>
               </component>
               <component>
                  <section ID="_e69316e7-1cdc-84b2-ec47-5ac38131e236">
                     <id root="ee89b8eb-3baf-001d-33dc-90e31f71d66a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.3 <content styleCode="italics">Clostridioides difficile</content> Associated Diarrhea</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile</content> associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including doxycycline, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antibacterial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="_689b21e3-de32-f161-0d0b-e9c642681e20">
                     <id root="0fbe7fde-878d-52e7-e12c-f03de8f287e0"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.4 Photosensitivity</title>
                     <text>
                        <paragraph>Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.</paragraph>
                     </text>
                     <effectiveTime value="20200803"/>
                  </section>
               </component>
               <component>
                  <section ID="_cc773d5b-5df9-c2a2-834b-d3359b4f5e9f">
                     <id root="3c576150-4419-f5ea-7913-136f40155888"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.5 Severe Skin Reactions</title>
                     <text>
                        <paragraph>Severe skin reactions, such as exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in patients receiving doxycycline. Fixed drug eruptions have occurred with doxycycline and have been associated with worsening severity upon subsequent administrations, including generalized bullous fixed eruption <content styleCode="italics">[See Adverse Reactions (<linkHtml href="#ADVERSE_REACTIONS">6</linkHtml>)]</content>. If severe skin reactions occur, discontinue doxycycline tablets  immediately and institute appropriate therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="_77e856af-98d6-4786-f6ab-0e6b567da04d">
                     <id root="cec4c0b9-a948-946e-e4ec-f2ed24ea39f6"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.6 Intracranial Hypertension</title>
                     <text>
                        <paragraph>Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracyclines including doxycycline. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin and doxycycline should be avoided because isotretinoin is also known to cause pseudotumor cerebri.</paragraph>
                        <paragraph>Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.</paragraph>
                     </text>
                     <effectiveTime value="20180814"/>
                  </section>
               </component>
               <component>
                  <section ID="_b547d64a-b707-7b3f-efed-34f830107712">
                     <id root="289adaab-d5b8-7b6c-014d-371d6b0fde02"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.7 Antianabolic Action</title>
                     <text>
                        <paragraph>The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.</paragraph>
                     </text>
                     <effectiveTime value="20200803"/>
                  </section>
               </component>
               <component>
                  <section ID="_013b7366-1662-643f-386e-316d84b85717">
                     <id root="19f3b552-94d3-3f33-cb36-5188f3787a90"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.8 Incomplete Suppression of Malaria</title>
                     <text>
                        <paragraph>Doxycycline offers substantial but not complete suppression of the asexual blood stages of <content styleCode="italics">Plasmodium</content> strains. </paragraph>
                        <paragraph>Doxycycline does not suppress <content styleCode="italics">P. falciparum</content>’s sexual blood stage gametocytes. Subjects completing this prophylactic regimen may still transmit the infection to mosquitoes outside endemic areas.</paragraph>
                     </text>
                     <effectiveTime value="20200803"/>
                  </section>
               </component>
               <component>
                  <section ID="_dc30eca9-fcf4-0081-eaa3-a3209759bb09">
                     <id root="0300a1ba-d76d-055a-6d34-f54514955c2e"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.9 Development of Drug-Resistant Bacteria</title>
                     <text>
                        <paragraph>Prescribing doxycycline in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                     </text>
                     <effectiveTime value="20200803"/>
                  </section>
               </component>
               <component>
                  <section ID="_b8327f04-d420-2c8d-9087-40a5c4178958">
                     <id root="42ef23d1-5f82-67cb-2496-494c5d36b834"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title> 5.10 Potential for Microbial Overgrowth  </title>
                     <text>
                        <paragraph>Doxycycline tabs and doxycycline caps may result in overgrowth of non-susceptible organisms, including fungi. If such infections occur, discontinue use and institute appropriate therapy.  
 </paragraph>
                     </text>
                     <effectiveTime value="20200804"/>
                  </section>
               </component>
               <component>
                  <section ID="_447b5438-9290-85ce-afbd-bc9769c92a93">
                     <id root="868c4971-53d1-8be3-111a-7e21fed4c335"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.11 Laboratory Monitoring for Long-Term Therapy</title>
                     <text>
                        <paragraph>In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal and hepatic studies should be performed.</paragraph>
                     </text>
                     <effectiveTime value="20200803"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ADVERSE_REACTIONS">
               <id root="25352d43-3f45-2115-5544-e8840eb2c729"/>
               <code code="34084-4" displayName="ADVERSE REACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions have been identified during clinical trials or post-approval use of tetracycline-class drugs, including doxycycline. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal</content>: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis,  inflammatory lesions (with monilial overgrowth) in the anogenital region, and pancreatitis. Hepatotoxicity has been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Superficial discoloration of the adult permanent dentition, reversible upon drug discontinuation and professional dental cleaning has been reported. Permanent tooth discoloration and enamel hypoplasia may occur with drugs of the tetracycline class when used during tooth development <content styleCode="italics">[See Warnings and Precautions (<linkHtml href="#_d193ecd5-24b0-f016-fb8f-c8f6e58c0425">5.1</linkHtml>)]</content>. Instances of esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline-class. Most of these patients took medications immediately before going to bed <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#_c0cc4249-f019-6d60-f53c-a0a160f6a9f9">2.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Skin:</content> Maculopapular and erythematous rashes, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, and erythema multiforme, and fixed drug eruption have been reported. Photosensitivity has been reported [see <content styleCode="italics">Warnings and Precautions</content> (<content styleCode="italics">
                        <linkHtml href="#_689b21e3-de32-f161-0d0b-e9c642681e20">5.4</linkHtml>
                     </content>)].</paragraph>
                  <paragraph>
                     <content styleCode="italics">Renal:</content> Rise in BUN has been reported and is apparently dose-related [see <content styleCode="italics">Warnings and Precautions</content> (<content styleCode="italics">
                        <linkHtml href="#_b547d64a-b707-7b3f-efed-34f830107712">5.7</linkHtml>
                     </content>)].</paragraph>
                  <paragraph>
                     <content styleCode="italics">Hypersensitivity reactions:</content> Urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, exacerbation of systemic lupus erythematosus, and drug reaction with eosinophilia and systemic symptoms (DRESS).</paragraph>
                  <paragraph>
                     <content styleCode="italics"/>
                     <content styleCode="italics">Blood:</content> Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported.</paragraph>
                  <paragraph>
                     <content styleCode="italics">I</content>
                     <content styleCode="italics">ntracranial Hypertension:</content> Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracyclines [see <content styleCode="italics">Warnings and Precautions</content> (<content styleCode="italics">
                        <linkHtml href="#_77e856af-98d6-4786-f6ab-0e6b567da04d">5.6</linkHtml>
                     </content>)].</paragraph>
                  <paragraph>
                     <content styleCode="italics">Thyroid Gland Changes:</content> When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands. No abnormalities of thyroid function are known to occur.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Psychiatric</content>: Depression, anxiety, suicidal ideation, insomnia, abnormal dreams, hallucination</paragraph>
               </text>
               <effectiveTime value="20250408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adverse reactions observed in patients receiving tetracyclines include anorexia, nausea, vomiting, diarrhea, rash, photosensitivity, urticaria, and hemolytic anemia. (<linkHtml href="#ADVERSE_REACTIONS">6</linkHtml>)<content styleCode="bold"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                           <content styleCode="bold"/>
                        </paragraph>
                        <paragraph/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="DRUG_INTERACTIONS">
               <id root="0307f4e0-f18d-8083-ebef-ed782ceebed9"/>
               <code code="34073-7" displayName="DRUG INTERACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250411"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <list>
                           <item>Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. (<linkHtml href="#_866d36bd-4286-cef4-91a5-4975fee9305a">7.1</linkHtml>)</item>
                           <item>Avoid co-administration of tetracyclines with penicillin. (<linkHtml href="#_6cbd934a-3566-c53c-ec65-45c6f7cda99f">7.2</linkHtml>)</item>
                           <item>Absorption of tetracyclines, including doxycycline is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations. (<linkHtml href="#_1b8eeab6-aeb9-058d-ddb0-0fc9f99cd554">7.3</linkHtml>)</item>
                           <item>Concurrent use of tetracyclines, including doxycycline may render oral contraceptives less effective. (<linkHtml href="#_626f4705-4e90-99d2-420f-56ce6195b77e">7.4</linkHtml>)</item>
                           <item>Barbiturates, carbamazepine and phenytoin decrease the half-life of doxycycline. (<linkHtml href="#_217f0f96-cc1e-ad22-f29f-49794c419ed6">7.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_866d36bd-4286-cef4-91a5-4975fee9305a">
                     <id root="2c64efe1-da48-265a-0a6a-c370ce58f826"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.1 Anticoagulant Drugs</title>
                     <text>
                        <paragraph>Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.</paragraph>
                     </text>
                     <effectiveTime value="20160316"/>
                  </section>
               </component>
               <component>
                  <section ID="_6cbd934a-3566-c53c-ec65-45c6f7cda99f">
                     <id root="0b10c199-da20-6f00-eb31-fa2c6f76aa17"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.2 Penicillin</title>
                     <text>
                        <paragraph>Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines, including doxycycline in conjunction with penicillin.</paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_1b8eeab6-aeb9-058d-ddb0-0fc9f99cd554">
                     <id root="af66cc64-ac3d-0b6d-65fa-230263b2c834"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.3 Antacids and Iron Preparations</title>
                     <text>
                        <paragraph>Absorption of tetracyclines, including doxycycline is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations.</paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_626f4705-4e90-99d2-420f-56ce6195b77e">
                     <id root="9c815ed9-8600-0144-583a-1fc63bf8b1a8"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.4 Oral Contraceptives</title>
                     <text>
                        <paragraph>Concurrent use of tetracyclines, including doxycycline may render oral contraceptives less effective.</paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_217f0f96-cc1e-ad22-f29f-49794c419ed6">
                     <id root="9929b24e-71a3-3b49-5b4d-974a479b13b6"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.5 Barbiturates and Anti-Epileptics</title>
                     <text>
                        <paragraph>Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.</paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="_5fb218fb-4391-ab3b-d0a2-a6a3e1fce027">
                     <id root="8556f736-5b0f-4202-62b5-db853d4f71f3"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.7 Drug and Laboratory Test Interactions</title>
                     <text>
                        <paragraph>False elevations of urinary catecholamines may occur due to interference with the fluorescence test.</paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="USE_IN_SPECIFIC_POPULATIONS">
               <id root="abaf158f-3f7b-b775-4d4b-7a10658ca042"/>
               <code code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20160928"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <list>
                           <item>Lactation: Breastfeeding is not recommended. (<linkHtml href="#_c492b5ca-d2c7-66ed-320c-447f1c99d148">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="PREGNANCY">
                     <id root="e00ea9d6-13c5-5198-9e1a-236e459786f6"/>
                     <code code="42228-7" displayName="PREGNANCY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold"/>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>Doxycycline hyclate tablets, like other tetracycline-class antibacterial drugs, may cause discoloration deciduous teeth, and reversible inhibition of bone growth when administered during the second and third trimester of pregnancy [see Warnings and Precautions <linkHtml href="#_d193ecd5-24b0-f016-fb8f-c8f6e58c0425">(5.1)</linkHtml> and <linkHtml href="#_e69316e7-1cdc-84b2-ec47-5ac38131e236">(5.2)</linkHtml>]. Available data from published studies over decades have not shown a difference in major birth defect risk compared to unexposed pregnancies with doxycycline exposure in the first trimester of pregnancy (see Data). There are no available data on the risk of miscarriage following exposure to doxycycline in pregnancy. Advise the patient of the potential risk to the fetus if Doxycycline hyclate tablets is used during pregnancy. <content styleCode="bold"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"/>
                        </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>A retrospective cohort study of 1,690 pregnant patients who received doxycycline prescriptions in the first trimester of pregnancy compared to an unexposed pregnant cohort showed no difference in the major malformation rate. There is no information on the dose or duration of treatment, or if the patients actually ingested the doxycycline that was prescribed. </paragraph>
                        <paragraph>Other published studies on exposure to doxycycline in the first trimester of pregnancy have small sample sizes; however, these studies have not shown an increased risk of major malformations.</paragraph>
                        <paragraph>The use of tetracyclines during tooth development (second and third trimester of pregnancy) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drug but has been observed following repeated short-term courses. [see Warnings and Precautions <linkHtml href="#_d193ecd5-24b0-f016-fb8f-c8f6e58c0425">(5.1</linkHtml>,<linkHtml href="#_4265d35a-2ae9-6486-35cf-60b34ceb56fd">5.2</linkHtml>)].</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity also has been noted in animals treated early in pregnancy.</paragraph>
                     </text>
                     <effectiveTime value="20200803"/>
                  </section>
               </component>
               <component>
                  <section ID="_3e735fb5-cf7e-9604-aaf4-6fb1214b1162">
                     <id root="e4d3633d-16a4-06b5-f01c-8a3c3d217a15"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on available published data, doxycycline is present in human milk. There are no data that inform the levels of doxycycline in breastmilk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for serious adverse reactions, including tooth discoloration and inhibition of bone growth, advise patients that breastfeeding is not recommended during treatment with Doxycycline hylcate tablets and for 5 days after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20200803"/>
                  </section>
               </component>
               <component>
                  <section ID="NURSING_MOTHERS">
                     <id root="22d76f91-9760-52ff-b3e7-c97a9100ff2f"/>
                     <code code="34080-2" displayName="NURSING MOTHERS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.3 Females and Males of Reproductive Potential </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infertility </content>
                        </paragraph>
                        <paragraph>Based on findings from a fertility study in animals, doxycycline may impair female and male fertility. The reversibility of this finding is unclear. [see Nonclinical Toxicology <linkHtml href="#CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY">(13.1)</linkHtml>].</paragraph>
                     </text>
                     <effectiveTime value="20200803"/>
                  </section>
               </component>
               <component>
                  <section ID="PEDIATRIC_USE">
                     <id root="e1545228-ee0f-095b-5e4d-6c2baf9dd535"/>
                     <code code="34081-0" displayName="PEDIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Because of the effects of drugs of the tetracycline-class on tooth development and growth, use doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_d193ecd5-24b0-f016-fb8f-c8f6e58c0425">5.1</linkHtml>,<linkHtml href="#_35633dc6-a659-dbb2-2852-3507ff5e1619"/>1.1) and Dosage and Administration (<linkHtml href="#_c0cc4249-f019-6d60-f53c-a0a160f6a9f9">2.1</linkHtml>, <linkHtml href="#_0b9d9d30-39a4-afb7-9662-04eaecf2f0cb"> 2.5</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20180814"/>
                  </section>
               </component>
               <component>
                  <section ID="GERIATRIC_USE">
                     <id root="2eb72f5f-1ae9-be9d-34da-cea041b180d6"/>
                     <code code="34082-8" displayName="GERIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of doxycycline hyclate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="OVERDOSAGE">
               <id root="347355bf-8c73-a2ca-93ff-3919361a83bb"/>
               <code code="34088-5" displayName="OVERDOSAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage.</paragraph>
               </text>
               <effectiveTime value="20160928"/>
            </section>
         </component>
         <component>
            <section ID="DESCRIPTION">
               <id root="6f3a4726-d50c-5b43-87b5-0c5220709e43"/>
               <code code="34089-3" displayName="DESCRIPTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Doxycycline hyclate tablets, USP contain doxycycline hyclate, USP a tetracycline class drug synthetically derived from oxytetracycline, in an immediate release formulation for oral administration.</paragraph>
                  <paragraph>The molecular formula of doxycycline hyclate is (C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>8</sub>, HCl)<sub>2</sub>•C<sub>2</sub>H<sub>6</sub>O•H<sub>2</sub>O and the molecular weight of doxycycline hyclate is 1025.87. The chemical name for doxycycline hyclate, USP is: 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2­- naphthacenecarboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate (USP).</paragraph>
                  <paragraph>The structural formula for doxycycline hyclate is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM526342451398"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 1: Structure of Doxycycline Hyclate</content>
                  </paragraph>
                  <paragraph>Doxycycline hyclate, USP is a yellow crystalline powder slightly soluble in ethanol, practically insoluble in chloroform and ether. </paragraph>
                  <paragraph>Doxycycline hyclate tablets, USP are available as 75 mg and 150 mg. Each 75 mg tablet contains 86.6 mg of doxycycline hyclate, USP equivalent to 75 mg of doxycycline. Each 150 mg tablet contains 173.1 mg of doxycycline hyclate, USP equivalent to 150 mg of doxycycline.  </paragraph>
                  <paragraph>Inactive ingredients in the tablet formulation are: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate and microcrystalline cellulose. </paragraph>
                  <paragraph>Film-coating solution for 75 mg contains: D&amp;C Yellow # 10 aluminum lake, FD&amp;C Blue # 1 aluminum lake, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.</paragraph>
                  <paragraph>Film-coating solution for 150 mg contains: ferric oxide yellow, indigotine aluminum lake (blue # 2), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.</paragraph>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20160928"/>
            </section>
         </component>
         <component>
            <section ID="CLINICAL_PHARMACOLOGY">
               <id root="05043b40-9e7e-f229-fed4-2a5bd8d5afd4"/>
               <code code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20160928"/>
               <component>
                  <section ID="MECHANISM_OF_ACTION">
                     <id root="781adb2b-8fa0-9cbb-db19-91086b65b568"/>
                     <code code="43679-0" displayName="MECHANISM OF ACTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Doxycycline is a tetracycline-class antimicrobial drug <content styleCode="italics">[see Microbiology (<linkHtml href="#_772e81ae-e6a8-9b1c-d6c0-95f933b5f987">12.4</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="PHARMACOKINETICS">
                     <id root="bbc4ef21-11cf-74d6-19c5-07f9455719d9"/>
                     <code code="43682-4" displayName="PHARMACOKINETICS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Doxycycline hyclate tablets: Following administration of a single 300 mg dose to adult volunteers, average peak plasma doxycycline levels were 3.0 mcg per mL at 3 hours, decreasing to 1.18 mcg per mL at 24 hours. The mean C<sub>max </sub>and AUC<sub>0-∞</sub> of doxycycline are 24% and 15% lower, respectively, following single dose administration of doxycycline hyclate tablets, 150 mg tablets with a high fat meal (including milk) compared to fasted conditions. The clinical significance of these decreases is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Excretion</content>
                        </paragraph>
                        <paragraph>Tetracyclines are concentrated in bile by the liver and excreted in the urine and feces at high concentrations and in a biologically active form. </paragraph>
                        <paragraph>Excretion of doxycycline by the kidney is about 40% per 72 hours in individuals with a creatinine clearance of about 75 mL per minute. This percentage may fall as low as 1% per 72 hours to 5% per 72 hours in individuals with a creatinine clearance below 10 mL per minute.</paragraph>
                        <paragraph>Studies have shown no significant difference in the serum half-life of doxycycline (range 18 to 22 hours) in individuals with normal and severely impaired renal function. Hemodialysis does not alter the serum half-life.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients </content>
                        </paragraph>
                        <paragraph>Population pharmacokinetic analysis of sparse concentration-time data of doxycycline following standard of care intravenous and oral dosing in 44 children (2-18 years of age) showed that allometrically-scaled clearance of doxycycline in children ≥2 to ≤8 years of age (median [range] 3.58 [2.27-10.82] L/h/70 kg, N=11) did not differ significantly from children &gt;8 to 18 years of age (3.27 [1.11-8.12] L/h/70 kg, N=33). For pediatric patients weighing ≤45 kg, body weight normalized doxycycline CL in those ≥2 to ≤8 years of age (median [range] 0.071 [0.041-0.202] L/kg/h, N=10) did not differ significantly from those &gt;8 to 18 years of age (0.081 [0.035-0.126] L/kg/h, N=8). In pediatric patients weighing &gt;45 kg no clinically significant differences in body weight normalized doxycycline CL were observed between those ≥2 to ≤8 years (0.050 L/kg/h, N=1) and those &gt;8 years of age (0.044 [0.014-0.121] L/kg/h, N=25). No clinically significant difference in CL differences between oral and IV were observed in the small cohort of pediatric patients who received the oral (N=19) or IV (N=21) formulation alone.</paragraph>
                     </text>
                     <effectiveTime value="20200803"/>
                  </section>
               </component>
               <component>
                  <section ID="_772e81ae-e6a8-9b1c-d6c0-95f933b5f987">
                     <id root="5d0db1b4-4878-2911-6d83-e7604faf354d"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action</content>
                        </paragraph>
                        <paragraph>Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Resistance</content>
                        </paragraph>
                        <paragraph>Cross resistance with other tetracyclines is common.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Antimicrobial Activity</content>
                        </paragraph>
                        <paragraph>Doxycycline has been shown to be active against most isolates of the following microorganisms, both <content styleCode="italics">in vitro</content> and in clinical infections <content styleCode="italics">[see Indications and Usage (<linkHtml href="#_ddd59e50-15bf-825b-e6f8-bc258f8f13aa">1</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Gram-negative Bacteria </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Acinetobacter </content>species<content styleCode="italics">
                              <br/>Bartonella bacilliformis <br/>Brucella </content>species<content styleCode="italics">
                              <br/>Campylobacter fetus <br/>Enterobacter aerogenes <br/>Escherichia coli <br/>Francisella tularensis <br/>Haemophilus ducreyi <br/>Haemophilus influenzae <br/>Klebsiella granulomatis <br/>Klebsiella </content>species<content styleCode="italics">
                              <br/>Neisseria gonorrhoeae <br/>Shigella </content>species<content styleCode="italics">
                              <br/>Vibrio cholerae <br/>Yersinia pestis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Gram-positive Bacteria </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Bacillus anthracis <br/>Listeria monocytogenes <br/>Streptococcus pneumoniae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Anaerobic Bacteria </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Clostridium </content>species<content styleCode="italics">
                              <br/>Fusobacterium fusiforme <br/>Propionibacterium acnes </content>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Other Bacteria</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nocardiae </content>
                           <content styleCode="italics">and</content> other aerobic <content styleCode="italics">Actinomyces</content> species <br/>
                           <content styleCode="italics">Borrelia recurrentis <br/>Chlamydophila psittaci <br/>Chlamydia trachomatis <br/>Mycoplasma pneumoniae</content>
                           <br/>
                           <content styleCode="italics">Rickettsiae</content> species <br/>
                           <content styleCode="italics">Treponema pallidum </content>
                           <br/>
                           <content styleCode="italics">Treponema pallidum</content> subspecies <content styleCode="italics">pertenue</content>
                           <br/>
                           <content styleCode="italics">Ureaplasma urealyticum </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Parasites </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Balantidium coli <br/>Entamoeba </content>species<content styleCode="italics">
                              <br/>Plasmodium falciparum</content>
                           <content styleCode="italics">*</content>
                           <br/>*Doxycycline has been found to be active against the asexual erythrocytic forms of <content styleCode="italics">Plasmodium falciparum</content>, but not against the gametocytes of <content styleCode="italics">P. falciparum</content>. The precise mechanism of action of the drug is not known.<br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Susceptibility Testing </content>
                        </paragraph>
                        <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.<content styleCode="bold"/>
                           <content styleCode="bold"/>
                           <sup/>
                           <br/>
                        </paragraph>
                        <paragraph/>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20200803"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="NONCLINICAL_TOXICOLOGY">
               <id root="14e981b7-a899-d47d-3690-dc573d6b32c7"/>
               <code code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20160928"/>
               <component>
                  <section ID="CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY">
                     <id root="260d7700-0df4-3bf7-5841-e750d36776ab"/>
                     <code code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term studies in animals to evaluate carcinogenic potential of doxycycline hyclate have not been conducted.</paragraph>
                        <paragraph>However, a 2 year carcinogenicity study with doxycycline administered daily by oral gavage to adult rats (20, 75, 200 mg/kg/day) demonstrated an increase in uterine polyps in female rats at 200 mg/kg/day (10 times the maximum recommended daily adult dose of doxycycline hyclate tablets based on body surface area comparison) with no change in tumor incidence in male rats at the same dose. A 2-year carcinogenicity study with doxycycline administered daily by oral gavage to adult male (maximum dose 150 mg/kg/day) and female (maximum dose 300 mg/kg/day) mice showed no changes in tumor incidence, at approximately 4 and 7 times the maximum recommended daily adult dose of doxycycline hyclate tablets, based on a body surface area comparison, respectively. </paragraph>
                        <paragraph>Mutagenesis and fertility studies have not been conducted with doxycycline hyclate tablets. Mutagenesis studies with doxycycline demonstrated no potential to cause genetic toxicity in an <content styleCode="italics">in vitro</content> point mutation study with mammalian cells or in an <content styleCode="italics">in vivo</content> micronucleus assay in CD-1 mice. However, data from an <content styleCode="italics">in vitro</content> mammalian chromosomal aberration assay conducted in CHO cells suggest that doxycycline is a weak clastogen. Oral administration of doxycycline to Sprague-Dawley rats showed adverse effects on fertility and reproduction including increased time for mating, reduced sperm motility, velocity and concentration as well as increased pre and post implantation loss. Reduced sperm velocity was seen at the lowest dosage tested, 50 mg/kg/day which is 2.5 times the maximum recommended daily adult dose of doxycycline hyclate tablets. Although doxycycline impairs the fertility of rats when administered at sufficient dosages, the effect of doxycycline on human fertility is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
               <component>
                  <section ID="ANIMAL_PHARMACOLOGY_AND_OR_TOXICOLOGY_SECTION">
                     <id root="966e447b-2f9a-b60e-f71e-ddc848569ee7"/>
                     <code code="34091-9" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>Hyperpigmentation of the thyroid has been produced by members of the tetracycline-class in the following species: in rats by oxytetracycline, doxycycline, tetracycline PO<sub>4</sub>, and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO<sub>4</sub>, and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.</paragraph>
                        <paragraph>Minocycline, tetracycline PO<sub>4</sub>, methacycline, doxycycline, tetracycline base, oxytetracycline HCl, and tetracycline HCl, were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was accompanied by high radioactive iodine uptake. Administration of minocycline also produced a large goiter with high radioiodine uptake in rats fed a relatively high iodine diet.</paragraph>
                        <paragraph>Treatment of various animal species with this class of drugs has also resulted in the induction of thyroid hyperplasia in the following: in rats and dogs (minocycline); in chickens (chlortetracycline); and in rats and mice (oxytetracycline). Adrenal gland hyperplasia has been observed in goats and rats treated with oxytetracycline.</paragraph>
                        <paragraph>Results of animal studies indicate that tetracyclines cross the placenta and are found in fetal tissues.</paragraph>
                     </text>
                     <effectiveTime value="20160928"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="REFERENCES">
               <id root="0393969b-f5db-2808-22f6-a4a250f15ff3"/>
               <code code="34093-5" displayName="REFERENCES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph>1 Friedman JM, Polifka JE. <content styleCode="italics">Teratogenic Effects of Drugs. A Resource for Clinicians (TERIS)</content>. Baltimore, MD: The Johns Hopkins University Press: 2000: 149-195. </paragraph>
                  <paragraph>2 Cziezel AE and Rockenbauer M. Teratogenic study of doxycycline. Obstet Gynecol 1997; 89: 524­- 528.</paragraph>
                  <paragraph>3 Horne HW Jr. and Kundsin RB. The role of mycoplasma among 81 consecutive pregnancies: a prospective study. <content styleCode="italics">Int J Fertil</content> 1980; 25: 315-317.</paragraph>
                  <paragraph>4 Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); [Last Revision Date 2018 Oct 31; cited 2019 Jun]. Doxycycline; LactMed Record Number: 100; [about 3 screens]. Available from: http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250408"/>
            </section>
         </component>
         <component>
            <section ID="HOW_SUPPLIED">
               <id root="45b54073-8637-704f-a045-cdc12f7cd1dc"/>
               <code code="34069-5" displayName="HOW SUPPLIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="underline"> How Supplied</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"/>Doxycycline hyclate tablets, USP 75　mg are light teal, round, biconvex film-coated tablets. Engraved "APO" on one side, "D75" on the other side. Each 75 mg tablet contains 86.6 mg of doxycycline hyclate, USP equivalent to 75 mg of doxycycline.</paragraph>
                  <paragraph>Bottles of 60 tablets: NDC 60505-4382-6</paragraph>
                  <paragraph>Bottles of 100 tablets: NDC 60505-4382-1</paragraph>
                  <paragraph>Bottles of 500 tablets: NDC 60505-4382-5</paragraph>
                  <paragraph>
                     <content styleCode="bold"/>
                     <content styleCode="none">Doxycycline hyclate tablets, USP 150 mg are mossy green, capsule shaped, biconvex film-coated tablets. Engraved "A" bisect "P" bisect "O" on one side, "1" bisect "5" bisect "0" on the other side. Each side of the functionally scored tablet has two parallel score lines for splitting into 3 equal portions.</content> Each 150 mg tablet contains 173.1 mg of doxycycline hyclate, USP equivalent to 150 mg of doxycycline.</paragraph>
                  <paragraph>
                     <content styleCode="bold"/>Bottles of 60 tablets: NDC 60505-4384-6</paragraph>
                  <paragraph>Bottles of 100 tablets: NDC 60505-4384-1</paragraph>
                  <paragraph>Bottles of 500 tablets: NDC 60505-4384-5</paragraph>
                  <paragraph>
                     <content styleCode="underline">Storage</content>
                  </paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F) excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from light and moisture. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</paragraph>
               </text>
               <effectiveTime value="20180814"/>
            </section>
         </component>
         <component>
            <section ID="INFORMATION_FOR_PATIENTS">
               <id root="74413bcf-1caa-6457-c72c-8e8561de4a0f"/>
               <code code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Instructions for Use). </paragraph>
                  <paragraph>
                     <content styleCode="underline">Important Administration and Safety Information for Patients and Caregivers</content>
                  </paragraph>
                  <paragraph>Advise patients taking doxycycline for malaria prophylaxis:</paragraph>
                  <list>
                     <item>that no present-day antimalarial agent, including doxycycline, guarantees protection against malaria.</item>
                     <item>to avoid being bitten by mosquitoes by using personal protective measures that help avoid contact with mosquitoes, especially from dusk to dawn (for example, staying in well-screened areas, using mosquito nets, covering the body with clothing, and using an effective insect repellent).</item>
                     <item>that doxycycline prophylaxis:<list>
                           <item>
                              <paragraph>should begin 1 day to 2 days before travel to the malarious area,</paragraph>
                           </item>
                           <item>
                              <paragraph>should be continued daily while in the malarious area and after leaving the malarious area,</paragraph>
                           </item>
                           <item>
                              <paragraph>should be continued for 4 further weeks to avoid development of malaria after returning from an endemic area,</paragraph>
                           </item>
                           <item>
                              <paragraph>should not exceed 4 months.</paragraph>
                           </item>
                        </list>
                     </item>
                  </list>
                  <paragraph>Advise all patients taking doxycycline:</paragraph>
                  <list>
                     <item>that doxycycline hyclate tablets (150 mg) can be broken into two-thirds or one-third at the scored lines to provide 100 mg or 50 mg strength doses, respectively.</item>
                     <item>to avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy if phototoxicity (for example, skin eruptions, etc.) occurs. Sunscreen or sunblock should be considered <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_689b21e3-de32-f161-0d0b-e9c642681e20">5.4</linkHtml>)].</content>
                     </item>
                     <item>to drink fluids liberally along with doxycycline to reduce the risk of esophageal irritation and ulceration <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ADVERSE_REACTIONS">6</linkHtml>)].</content>
                     </item>
                     <item>that the absorption of tetracyclines is reduced when taken with foods, especially those that contain calcium <content styleCode="italics">[see Drug Interactions (<linkHtml href="#_1b8eeab6-aeb9-058d-ddb0-0fc9f99cd554">7.3</linkHtml>)]</content>. However, the absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk <content styleCode="italics"> [see Clinical Pharmacology (<linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>)].</content>
                     </item>
                     <item>that if gastric irritation occurs, doxycycline may be given with food or milk <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>)].</content>
                     </item>
                     <item>that the absorption of tetracyclines is reduced when taken with antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations <content styleCode="italics">[see Drug Interactions (<linkHtml href="#_1b8eeab6-aeb9-058d-ddb0-0fc9f99cd554">7.3</linkHtml>)].</content>
                     </item>
                     <item>that the use of doxycycline might increase the incidence of vaginal candidiasis.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Tooth Discoloration and Inhibition of Bone Growth </content>
                  </paragraph>
                  <paragraph>Advise patients that Doxycycline hyclate tablets, like other tetracycline-class drugs, may cause permanent tooth discoloration of deciduous teeth and reversible inhibition of bone growth when administered during pregnancy. Tell your healthcare provider right away if you become pregnant during treatment [see Warnings and Precautions (<linkHtml href="#_d193ecd5-24b0-f016-fb8f-c8f6e58c0425">5.1,</linkHtml>
                     <linkHtml href="#_4265d35a-2ae9-6486-35cf-60b34ceb56fd">5.2)</linkHtml> and Use in Specific Populations (<linkHtml href="#PREGNANCY">8.1,</linkHtml>
                     <linkHtml href="#PEDIATRIC_USE"> 8.4)]</linkHtml>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation </content>
                  </paragraph>
                  <paragraph>Advise women not to breastfeed during treatment with Doxycycline hyclate tablets and for 5 days after the last dose [see Use in Specific Populations <linkHtml href="#_c492b5ca-d2c7-66ed-320c-447f1c99d148">(8.2)</linkHtml>].</paragraph>
                  <paragraph>
                     <content styleCode="underline">Diarrhea</content>
                  </paragraph>
                  <paragraph>Advise patients that diarrhea is a common problem caused by antibacterial drugs which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterial drugs, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of antibacterial. If this occurs, patients should contact their physician as soon as possible.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Development of Resistance</content>
                  </paragraph>
                  <paragraph>Counsel patients that antibacterial drugs including doxycycline should only be used to treat bacterial infections. They do not treat viral infections (for example, the common cold). When doxycycline is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by doxycycline or other antibacterial drugs in the future.</paragraph>
                  <paragraph>All registered trademarks in this document are the property of their respective owners.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX INC. <br/>DOXYCYCLINE HYCLATE TABLETS, USP <br/>75 mg and 150 mg</content>
                  </paragraph>
                  <table width="40%">
                     <tbody>
                        <tr>
                           <td>Manufactured by: </td>
                           <td>Manufactured for:</td>
                        </tr>
                        <tr>
                           <td>Apotex Inc.</td>
                           <td>Apotex Corp.</td>
                        </tr>
                        <tr>
                           <td>Toronto,　Ontario</td>
                           <td>Weston, Florida</td>
                        </tr>
                        <tr>
                           <td>Canada M9L 1T9 </td>
                           <td>USA 33326</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <br/>Rev. 5</paragraph>
               </text>
               <effectiveTime value="20250408"/>
            </section>
         </component>
         <component>
            <section ID="_111db304-ab0a-6aad-612f-d8bca87952b0">
               <id root="a7ef1356-0636-8662-0833-a9ba462aec94"/>
               <code code="42230-3" displayName="SPL PATIENT PACKAGE INSERT SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">FDA-Approved Patient Labeling </content>
                     <content styleCode="bold">
                        <br/>
                        <content styleCode="bold">Instructions for Use</content>
                        <br/>DOXYCYCLINE HYCLATE TABLETS, USP </content>
                     <br/>(dox" i sye’ kleen hye’ klate) <content styleCode="bold"/>
                     <br/>
                     <content styleCode="bold">for oral use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"/>Read this Instructions for Use before you start using doxycycline hyclate tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.</paragraph>
                  <paragraph>Note:</paragraph>
                  <list>
                     <item>Your healthcare provider may need to change your dose of doxycycline hyclate tablets during treatment as needed.</item>
                     <item>Doxycycline hyclate tablets can be taken whole or broken at scored lines. </item>
                     <item>Doxycycline hyclate tablets are marked with scored lines and may be broken at these scored lines to provide the following doses:</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">150 mg treatment (take the entire whole tablet)</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM527326191201"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 mg treatment (take two-thirds of the tablet)</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM694501683217"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">50 mg treatment (take one-third of the tablet)</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM300771129067"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">How to break your doxycycline hyclate tablet:</content>
                  </paragraph>
                  <list>
                     <item>Hold the tablet between your thumb and index finger close to the scored line for your dose of doxycycline hyclate tablet as shown above. </item>
                     <item>Apply enough pressure to break the tablet at the scored line.</item>
                     <item>
                        <content styleCode="bold">Do not</content>
                        <content styleCode="none"> break the doxycycline hyclate tablet in any other way.</content>
                     </item>
                  </list>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>All registered trademarks in this document are the property of their respective owners.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX INC. <br/>DOXYCYCLINE HYCLATE TABLETS, USP <br/>75 mg and 150 mg</content>
                  </paragraph>
                  <table width="70%">
                     <tbody>
                        <tr>
                           <td>Manufactured by: </td>
                           <td>Manufactured for:</td>
                        </tr>
                        <tr>
                           <td>Apotex Inc.<br/>Toronto, Ontario <br/>Canada M9L 1T9 </td>
                           <td>Apotex Corp.<br/>Weston, Florida <br/>USA 33326</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Rev. April 2025 <br/>Rev. 5</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250408"/>
            </section>
         </component>
         <component>
            <section ID="_91a0c2ee-d900-fcd0-6f33-008b079dd1a1">
               <id root="7b44af89-376d-12ed-1a23-8d7a294237e3"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION</title>
               <text>
                  <paragraph>Representative sample of labeling (see <linkHtml href="#HOW_SUPPLIED">HOW SUPPLIED</linkHtml> section for complete listing): </paragraph>
                  <paragraph>PRINCIPAL DISPLAY PANEL - 75 mg BOTTLE LABEL </paragraph>
                  <paragraph>APOTEX CORP.,</paragraph>
                  <paragraph>NDC No. 60505-4382-6</paragraph>
                  <paragraph>Doxycycline Hyclate Tablets, USP</paragraph>
                  <paragraph>75 mg </paragraph>
                  <paragraph>Rx Only </paragraph>
                  <paragraph>60 Tablets </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM245582140766"/>
                  </paragraph>
               </text>
               <effectiveTime value="20160928"/>
            </section>
         </component>
         <component>
            <section ID="_34d43690-ed4e-4086-bb2e-62aed2750bf6">
               <id root="3f81a8a1-4e48-008e-8f39-041f775e1b83"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION</title>
               <text>
                  <paragraph>Representative sample of labeling (see HOW SUPPLIED section for complete listing): </paragraph>
                  <paragraph>PRINCIPAL DISPLAY PANEL - 150 mg BOTTLE LABEL </paragraph>
                  <paragraph>APOTEX CORP.,</paragraph>
                  <paragraph>NDC No. 60505-4384-6</paragraph>
                  <paragraph>Doxycycline Hyclate Tablets, USP</paragraph>
                  <paragraph>150 mg </paragraph>
                  <paragraph>Rx Only </paragraph>
                  <paragraph>60 Tablets </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM947205434919"/>
                  </paragraph>
               </text>
               <effectiveTime value="20160928"/>
            </section>
         </component>
      </structuredBody>
   </component>
</document>